Table 1.
Patient characteristics.
| Total (n = 36) | |
|---|---|
| Age, y | |
| Median (range) | 67 (30–84) |
| ≥65 | 20 (55.6) |
| Sex, n (%) | |
| Male | 20 (55.6) |
| Female | 16 (44.4) |
| Previous treatment regimens, n (%) | |
| 1 | 19 (52.8) |
| ≥2 | 17(47.2) |
| Primary cancer, n (%) | |
| Gastric | 18 (50.0) |
| Colorectal | 13 (36.1) |
| Small intestine | 2 (5.6) |
| Cholangiocarcinoma | 2 (5.6) |
| Pancreatic | 1 (2.8) |
| ECOG PS, n (%) | |
| 0 | 23 (63.9) |
| 1 | 13 (36.1) |
| Surgery on primary tumor, n (%) | |
| No | 14 (38.9) |
| Yes | 22 (61.1) |
| Metastatic sites, n (%) | |
| Liver | 5 (13.9) |
| Lung | 5 (13.9) |
| Peritoneal | 16 (44.4) |
| Lymph node | 29 (80.6) |
| Number of metastatic organs, n (%) | |
| 1 | 19 (52.8) |
| ≥2 | 17 (47.2) |
| PD-L1 CPS, n (%) | |
| CPS < 1 | 7 (19.4) |
| 1 ≤ CPS < 10 | 5 (13.9) |
| CPS ≥ 10 | 23 (63.9) |
| Missing | 1 (5.3) |
| TMB, mutations/Mb (range) | 38.7 (3.6–93.0) |
| Treatment, n (%) | |
| Nivolumab | 6 (16.7) |
| Pembrolizumab | 24 (66.7) |
| Pembrolizumab with napabucasin | 6 (16.7) |
Abbreviations: CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; PS, Performance status; TMB, tumor mutational burden.